Key result
Review details the pharmacology and pharmacokinetics of dronedarone for paroxysmal or persistent AF.
This review summarizes the pharmacological, pharmacodynamic, and pharmacokinetic properties of dronedarone for the treatment of atrial fibrillation.
Provides dronedarone reference for AF clinicians; leaves open need for updated efficacy trials.
Dronedarone, a benzofuran containing chemical compound, is a derivative of amiodarone which is classified as a Class III antiarrhythmic agent. It is prescribed to the cardiovascular patients who have paroxysmal or persistent atrial fibrillation to lower the chances of hospitalization. Amiodarone, sotalol, procainamide dofetilide, quinidine, ibutilide, flecainide, and propafenone are the other useful medicinal products used to treat atrial fibrillation or cardiac arrhythmia. Dronedarone was approved for clinical use in atrial fibrillation by the Food and Drug Administration in 2009. The generic name for dronedarone is Multaq (Sanofi Aventis). This article briefly highlights the important pharmacological, pharmacodynamic and pharmacokinetic properties of dronedarone.
No takes yet. Share an insight, caveat, or question.
Iram et al. (2016) conducted a review in Atrial fibrillation. Dronedarone was evaluated. This review highlights the pharmacological, pharmacodynamic, and pharmacokinetic properties of dronedarone, a Class III antiarrhythmic agent used for paroxysmal or persistent atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: